Company Overview - Baixin International Holdings Limited primarily operates in investment holding, with two main business segments in China: (1) pharmaceutical distribution and (2) pharmaceutical manufacturing [2] Financial Performance - As of December 31, 2024, Baixin International reported total revenue of 86.554 million yuan, a year-on-year decrease of 33.13% [1] - The net profit attributable to shareholders was -15.313 million yuan, reflecting a significant year-on-year decline of 751.62% [1] - The gross profit margin stood at 19.71%, while the debt-to-asset ratio was 175.72% [1] Stock Performance - On July 25, the stock price closed at 0.042 HKD per share, marking an increase of 44.83% with a trading volume of 12.208 million shares and a turnover of 483,900 HKD, showing a volatility of 62.07% [1] - Over the past month, the cumulative increase in stock price was 0%, and the year-to-date decline was 38.3%, underperforming the Hang Seng Index by 27.95% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry (TTM) is 3.27 times, with a median of 6.65 times [1] - Baixin International's P/E ratio is -2.59 times, ranking 145th in the industry [1] - Comparatively, other companies in the industry have the following P/E ratios: Qianwei Pharmaceutical (1.22), Kingsray Biotechnology (1.74), Dongrui Pharmaceutical (3.35), Dajiankang International (6.61), and Jilin Changlong Pharmaceutical (6.65) [1]
百信国际（00574.HK）7月25日收盘上涨44.83%，成交48.39万港元